Clinical trial
Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage…
NCT00428194 · Masonic Cancer Center, University of Minnesota, Other · Withdrawn
Key facts
| NCT number | NCT00428194 |
|---|---|
| Title | Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer |
| Official title | Erlotinib in Combination With Cisplatin as Radiosensitizing Agents in Women Receiving Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Cervix; A Phase I Trial |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Drug, Procedure |
| Interventions | cisplatin, erlotinib hydrochloride, radiation therapy |
| Enrollment | 0 |
| Start date | Jan 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jan 29, 2007 |
| Last update posted | Nov 29, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: